Evidence map›Paper›PMID 41754476›Full record

ArticlePathogens (Basel, Switzerland)2026

A Cross-Sectional Study of Rift Valley Fever Exposure in Humans and Livestock in Southwestern Uganda Using a One Health Approach: Evidence of Elevated Seroprevalence Outside Recognized Outbreak Periods.

Luke Nyakarahuka, Silvia Situma, Raymond Odinoh, Barnabas Bakamutumaho, Carolyne Nasimiyu, Jeanette Dawa, Justine Okello, Honest Kemiyondo, Alex Tumusiime, Mutesi Joanita and 6 more

Abstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Luke NyakarahukaUganda Virus Research Institute, Entebbe P.O. Box 49, Uganda.
Silvia SitumaCenter for Research in Emerging Infectious Diseases East and Central Africa, Nairobi 00202, Kenya.ORCID 0000-0002-9257-4647
Raymond OdinohCenter for Research in Emerging Infectious Diseases East and Central Africa, Nairobi 00202, Kenya.
Barnabas BakamutumahoUganda Virus Research Institute, Entebbe P.O. Box 49, Uganda.
Carolyne NasimiyuCenter for Research in Emerging Infectious Diseases East and Central Africa, Nairobi 00202, Kenya.ORCID 0000-0002-7559-3109
Jeanette DawaCenter for Research in Emerging Infectious Diseases East and Central Africa, Nairobi 00202, Kenya.
Justine OkelloUganda Virus Research Institute, Entebbe P.O. Box 49, Uganda.ORCID 0000-0001-6218-8318
Honest KemiyondoDepartment of Animal Health and Production, Ministry of Agriculture, Animal Industry and Fisheries, Entebbe P.O. Box 513, Uganda.
Alex TumusiimeUganda Virus Research Institute, Entebbe P.O. Box 49, Uganda.
Mutesi JoanitaUganda Virus Research Institute, Entebbe P.O. Box 49, Uganda.
Jackson KyondoUganda Virus Research Institute, Entebbe P.O. Box 49, Uganda.
John KayiwaUganda Virus Research Institute, Entebbe P.O. Box 49, Uganda.ORCID 0000-0002-1840-1801
David OdongoUganda Virus Research Institute, Entebbe P.O. Box 49, Uganda.
Deo Birungi NdumuDepartment of Animal Health and Production, Ministry of Agriculture, Animal Industry and Fisheries, Entebbe P.O. Box 513, Uganda.
Kariuki M NjengaCenter for Research in Emerging Infectious Diseases East and Central Africa, Nairobi 00202, Kenya.
Robert F BreimanRollins School of Public Health, Emory University, 1518 Clifton Rd NE., Atlanta, GA 30322, USA.ORCID 0000-0002-7099-2936

Funding

Emerging Infectious Diseases Research Center - East and Central AfricaU01AI151799 · NIAID · WASHINGTON STATE UNIVERSITY · PI M KARIUKI NJENGA · 2020 to 2026
$10.4M
U.S. National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIAID/NIH), through the Centre for Research in Emerging Infectious Diseases-East and Central Africa U01AI151799
6 · The paper itself

Abstract

Rift Valley fever (RVF) transmission has intensified in southwestern Uganda since 2016. To quantify human and livestock exposure and associated risks, we conducted a cross-sectional serosurvey in Isingiro, Kabale and Rubanda districts between October and November 2023. A total of 766 humans and 2383 livestock were sampled and tested for RVF antibodies using ELISA, with structured questionnaires capturing demographic, behavioral and environmental data. Human seroprevalence was 11.5% (88/766), varying by district (13.8% Isingiro, 11.8% Rubanda, 6.8% Kabale;

Indexed as

LivestockRift Valley FeverRift Valley fever virusAdolescentAdultAnimalsAntibodies, ViralCattleChildChild, PreschoolCross-Sectional StudiesDisease OutbreaksFemaleGoatsHumansMaleAntibodies, Viralcattleepidemiologylivestockone healthrift valley feverrisk factorsseroprevalenceUgandavector-borne diseaseszoonotic diseases

Identifiers

PMID41754476
PMCPMC12943168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.